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Abstract 
Older adults with multimorbidity, polypharmacy, and complex health needs are the major consumer 
of health care. Ensuring that medicines are used safely, effectively, and delivered efficiently in this 
population is challenging. In this context, the approach to medicines delivery should seek to 
overcome some of the difficulties of delivering medicines to older people, and ensure each 
medication is delivered by the optimal and most convenient route for the patient in question. 
However, this poses significant obstacles, as the development of medicines suitable for use in older 
populations does not often account for complex health needs, potential challenges in relation to 
drug disposition, safety of excipients and limitations with practical usability of dosage forms. The 
objective of this review is to summarise and discuss current challenges and novel approaches to 
delivering medications to older adults.  
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1. Introduction 
Older adults with multimorbidity, polypharmacy (multiple medicine use), functional impairment, and 
complex health needs are the major consumers of health care. Ensuring safe and effective medicine 
use in this patient group requires balance between treating multiple chronic conditions and 
mitigating the risks of developing medicine-related problems. According to the World Health 
Organisation (WHO), unsafe medication practices and medication errors are a leading cause of injury 
and avoidable harm in health care systems across the world, resulting in costs in excess of $42 billion 
USD annually [1]. In response to this, WHO has established Medication Without Harm as the theme 
for the third Global Patient Safety Challenge to reduce severe avoidable medication-related harm by 
50% globally in the next 5 years, with reducing polypharmacy being identified as one of the target 
priority areas [1]. Regardless of the approach used to measure polypharmacy among older adults, 
inappropriately high rates of polypharmacy have been consistently reported for several decades 
despite clear recognition of unsafe medication practices [2]. In Australia, polypharmacy (use of five 
or more medicines) is identified in 42.5% of older adults living in the community [3]. Among 
Americans aged 65 years and older, from 1999-2000 to 2011-2012, polypharmacy (use of five or 
more medicines) increased from 24.0% to 39.0% [4]. Considering the increasing trends in medication 
use, hyperpolypharmacy, which refers to the use of 10 or more medications, is increasingly being 
reported. Among older Australian adults living in the community, the prevalence of 
hyperpolypharmacy (use of 10 or more medicines) is 4.5%, [3] compared to 23.8% among patients 
admitted to acute general medical hospital services [5]. Prescription medications are also 
increasingly used throughout Europe, with approximately 47.4% of older adults living in the 
community exposed to polypharmacy (use of five or more medicines), and 8.6% to 
hyperpolypharmacy (use of 10 or more medicines) [6]. 
 
. . Managing polypharmacy in older adults is complex: there is limited clinical evidence to support 
the use of complex medication regimens to manage older people with multimorbidity, while there is 
increasing evidence of harm, including an increased risk of an adverse event occurring, such as 
falling, frailty, functional impairment, hospitalization and even mortality [2]. An additional burden to 
ensuring the safety and efficacy of polypharmacy in older populations is ensuring appropriate 
delivery of medicines to older adults, and appropriate handling of medications by older adults and 
their caregivers. Medicines should be delivered at the correct dose and by the optimal and most 
convenient route of delivery for the patient in question. This process is undoubtedly more complex 
for older adults, as owing to multimorbidity and subsequent polypharmacy, the medication dosage 
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regimens are often complex. Medication complexity is also related to number of daily administration 
times, drug formulations, need to split or crush tables or need to administer drugs at specific times 
in relation to food intake or time of day. Approaches to delivering drugs to older people can be 
challenging: certain medicines such as inhalers, eye drops and self-administered injections require 
coordination and manual dexterity, as well as other physiological characteristics, such as the ability 
to swallow, sufficient inspiratory flow rate and adequate vision. Ideally, formulations should be 
suitably designed and acceptable to patients to ensure they reflect the physiological, physical, and 
social challenges of ageing. Indeed, criteria to inform development of drug formulations tailored for 
older populations have been proposed (Figure 1) [7]; some of the key components that should be 
considered include bioavailability, acceptability, dose adaptation and administration, socio-cultural 
acceptability, and product information.  
 
Figure 1: Criteria to inform pharmaceutical development of drug formulations. (Adapted from 
Breitkreut J et al 2007). 
 
In relation to designing specific pharmaceutical products for older people, it is essential that 
potential handling issues, different dosing requirements and the challenges of administration issues 
are considered and overcome [8]. To address this, efforts around medicines development have 
sought to incorporate the needs of older adults when designing new pharmaceutical products [9]. 
This acknowledgement is significant, and it is important that this progress continues to ensure 
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medicines are designed to account for the challenges of ageing to ensure they can be safely and 
effectively used by older people. In the sections below, we discuss the current challenges of 
delivering medicines in older people with respect to the natural process of ageing, multimorbidity, 
and patient-related factors. Finally, we consider how strategies can by employed by both a 
pharmaceutical industry and patient perspective to overcome these challenges to ensure medicines 
are delivered safely, effectively, and efficiently to older people. 
 
2. Age-related changes that influence drug delivery and formulation in older people 
With the normal process of ageing, there are several physiological, biological, physical and 
psychological changes that occur, which can have an impact on a patient’s ability to achieve the best 
possible outcome from their medicine. The key physiological changes associated with ageing, and 
how such changes are likely to impact on the use and delivery of medicines in older people are 
briefly outlined in Table 1 [10]. With respect to pharmacokinetic changes, reduced hepatic and renal 
clearance are generally the most significant changes, and these are likely to affect the half-life, 
maintenance dose and dosing interval of a drug. The main changes in oral bioavailability with ageing 
result from a reduced hepatic function (reduced blood flow, and mass): the bioavailability of drugs 
that undergo first pass metabolism has the potential to be significantly increased. The changes in 
volume of distribution are smaller and affect the drug half-life and loading doses. The clinical effects 
of age-related pharmacodynamic changes on drug delivery are not as well established, although it is 
known that such changes include altered drug-receptor interactions, changes in post-receptor 
signalling, reduced physiological reserve and impaired homeostatic mechanics. 
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Table 1: Impact of ageing on pharmacokinetics and pharmacodynamics 
Pharmacology Physiological changes Drug examples 
Pharmacokinetics   
Absorption Reduced gastro-intestinal surface, 
gastric acid production, saliva 
production 
Reduced gastric emptying 
 
Increased gastric pH 
Vitamin B12, iron 
Distribution Reduced renal and hepatic blood flow 
Reduced albumin water levels 
Reduced volume of distribution for 
water soluble drugs 
 
Increased body fat/water ratio 
Increased volume of distribution for 
lipid soluble drugs 
Diazepam, lignocaine, digoxin, 
paracetamol 
Metabolism Reduced hepatic volume and blood 
flow 
Reduced hepatic mass 
Morphine, diazepam, 
imipramine 
Excretion Reduced renal blood flow and 
glomerular filtration  
Cephalexin, digoxin 
Pharmacodynamics   
 Reduced resilience to external 
stressors 
Increased sensitivity to centrally active 
drugs 
Anticholinergic drugs, sedative 
drugs (e.g. benzodiazepines, 
opioids), beta-blockers (e.g. 
metoprolol) 
 
In addition, in older people, many medical conditions can impair individuals’ ability to take 
medications as intended. Medications handling and administration can be affected by chronic 
disease including dementia, Parkinson’s disease, stroke, oesophageal disease (e.g. gastro-
oesophageal reflux disease), presence of visual and cognitive impairments and swallowing 
difficulties. Indeed, during the normal process of ageing, the swallowing reflex can change as a 
consequence of loss of muscle mass and reduction in the elasticity of connective tissue, thus 
effecting the transition of bolus down the oesophagus. For example, previous studies have identified 
dysphagia or impaired swallowing function in 15.0% of a general older population [11], compared to 
30.0% of older people admitted to hospital [12], and 68.0% of nursing home residents [13]. A recent 
review reported the difficulty in swallowing oral medications among older adults ranged between 
10.0% and 40.0% [14]. Evidence suggests that problems with swallowing oral dosages occur in one 
third of older patients which requires modification of the dosage form in terms of capsule opening 
and tablet crushing [15]. This may result in oral dosage forms being modified (e.g. tablets crushed or 
split) to facilitate administration to patients with difficulty swallowing or to tailor the dose to the 
patient’s requirements. Studies show that 18.0% of aged care residents in Australia have received 
7 
 
crushed tablets [16], compared to 32.0% of older inpatients in France [17]. Tablet splitting is also 
common in older adults. In a Canadian study of 370 nursing home residents 35.0% of residents 
received at least one split medication [18]. In addition to disease-related swallowing difficulties of 
medicines, other factors, such as having a previous bad experience of using a medication or disliking 
the idea of taking medicines, can also contribute to swallowing difficulties in older people [19]. 
Tablet size, shape and density, can also lead to swallowing difficulties. In addition to the physical 
characteristics of a tablet – such as the size, shape, and density - the colour of a tablet has also been 
associated with swallowing difficulties – previous studies have reported a white colour as the most 
popular colour choice for tablets among older adults [20].  
 
Poor oral health may also contribute to swallowing difficulties in older people. The prevalence of 
xerostomia or dry mouth among community-dwelling adults ranges between 17.0% to 40.0% [21]. In 
older people, many medicines can cause dry mouth , which, in turn, can contribute to swallowing 
difficulties. Indeed, the use of benzodiazepines may affect the swallowing function secondary to the 
depressive action on the central nervous system [22]. Moreover, the use of antipsychotic 
medications in older people has been associated with oropharyngeal dysphagia [23, 24]. 
Interestingly, use of certain medications, such as beta-blockers, maybe associated with improved 
swallowing process in older people [25]. A potential mechanism of this effect is that beta-blockers 
reduce thickness of oral, nasal and pulmonary secretions, which may improve the swallowing 
function of older patients.  
 
One approach to overcoming swallowing difficulties in older people is to use a liquid formulation; 
however, there are challenges in this approach, including aspiration secondary to inadequate 
protection of the airway during swallowing [15]. Other routes of administration, such as transdermal 
or parenteral drug delivery, are potentially beneficial in older people with swallowing difficulties. 
The transdermal route has good potential in older patients – and their caregivers – as it is simple and 
painless to use. The parenteral route, which is also occasionally used when an older adult has 
swallowing difficulties, may not be appropriate for everyone: as a result of low body weight and 
decreased muscle mass, frail older people can have limited venous access. Frailty, which is a 
multifactorial syndrome associated with functional impairment and increased susceptibility to 
disease, disability and mortality, can also impact on self-administration capability of medicines 
among older people [26]. The use of novel technologies, such as multiparticulate dosage forms, 
could also play a major role in delivering medicines for older adults. Multiparticulate systems, such 
as micropellets, offer an ideal size range for ease of administration; they also offer accurate dose 
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delivery in uniform dose units, including sachet, capsules, and can be manufactured in range of dose 
strengths which offers important flexibility in delivering medicines to older people. Medicine 
lubricant can be used to mitigate swallowing difficulties. One advantage to using medicine lubricant 
such as Gloup available in Australia, is that it reduces the need for medicine alteration, and it may 
allow the patient to swallow the medicine without the need for crushing. Moreover, use of mixing 
vehicles such as delivering medicines with food or drink may overcome swallowing difficulties. 
However, it is important to consider how this may impact on drug bioavailability. For instance, use of 
fruit juices such as grapefruit has been shown to affect drug absorption [27]. Also, there is a need for 
specific information to be included in the approved product information regarding appropriate food 
quantity that should be used in mixing vehicles. 
 
3. The challenges of multimorbidity and drug delivery in an older population 
 
Multimorbidity, defined as the co-existence of two or more chronic conditions, is highly prevalent 
among older adults across the world [28]. The most common chronic conditions found in older 
people include: hypertension, hyperlipidaemia, ischaemic heart disease, diabetes arthritis and heart 
failure [29]. Overall, the number of older people with multimorbidity varies from country to country, 
with studies reporting prevalence rates of greater than 50.0% [30] [31], with higher prevalence 
reported in certain populations, such as nursing home residents (82.0%) [32] and amongst people 
with intellectual disabilities (99.0%) [33]. . By 2035, it is anticipated that the number of people living 
with two or more chronic conditions will increase by 86.4% - with the biggest increases observed for 
cancer (an increase by 179.4%) and diabetes (an increase by 118.1%) [34]. Why is this important in 
relation to delivering medicines to older people? It is has been demonstrated in the literature that 
the presence of multimorbidity is associated with a number of health harms, including a reduced 
quality of life [35], mortality [36], increased healthcare utilisation [37], and higher rates of adverse 
drug events [38]. In addition, in older adults, the use of polypharmacy in the context of multiple 
chronic conditions can be problematic owing to the potential for developing drug-disease 
interactions. It is possible that specific chronic conditions can influence the treatment type, dose or 
formulation choice for another chronic condition. 
 
Table 2: Examples of potential drug-disease interactions  occurring with NSAIDs in older people, and 
strategies employed to mitigate against them. 
Disease state Potential consequence of Strategies employed to 
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using NSAIDs overcome in older people 
Asthma Beta-blockers Use another class of analgesic 
medication; use medication 
topically rather than systemically 
Chronic renal impairment Sodium and fluid retention, 
reduced eGFR; worsening of 
disease 
Avoid long term use of NSAIDs; 
use medication topically rather 
than systemically; use another 
class of analgesic 
Congestive heart failure Increased fluid retention; 
worsening of disease 
Avoid long term use of NSAIDs; 
use medication topically rather 
than systemically; use another 
class of analgesic 
Hypertension Increased blood pressure; 
worsening of disease 
Monitor blood pressure 
regularly; avoid long-term use, if 
possible 
Peptic ulcer disease (PUD) GI irritation; worsening of 
disease 
Consider using gastro-protective 
treatment (such as a PPI or 
H2RA) 
Abbreviations: CNS, central nervous system; NSAIDs, non-steroidal anti-inflammatory drugs; eGFR, 
estimated glomerular filtration rate; GI, gastrointestinal irritation; PPI, proton pump inhibitor; H2RA, 
H2 receptor antagonist. Examples taken from [39], [40], [41]. 
 
To use non-steroidal anti-inflammatory drugs (NSAIDs) as an example – a medication commonly 
prescribed for older people –, these medications are associated with several clinically significant 
drug-disease interactions, , particularly in the presence of multimorbidity (Table 2). Worldwide, 
there are many examples of NSAIDs available on the market, which are widely used to treat pain and 
inflammation; perhaps the most notable adverse effect of the NSAIDs is gastrointestinal (GI) 
irritation, mediated through cyclooxygenase (COX) inhibition, which reduces the levels of GI 
protective prostaglandins. These GI effects are further compounded in older people as previously 
discussed due to the acidic nature of NSAIDs, and the delayed gastric emptying observed in older 
people, as discussed in the previous section. Furthermore, as prostaglandins also dilate the afferent 
arterioles of the glomeruli of the kidney, the use of NSAIDs has the potential to alter kidney function 
– potentially leading to renal impairment; common effects of this include sodium (and thus fluid) 
retention, and possible hypertension [42]. In view of these well-established disadvantages, some 
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treatment protocols advocate the use of other analgesics to manage pain in older people; perhaps 
the most common is the use of regular paracetamol, although the utility of this approach has 
recently been questioned [43]. If NSAIDs are indicated in older people, a simple – but effective – 
approach to drug delivery is to reduce the potential for the systematic absorption of NSAIDs, thereby 
reducing the risk of adverse drug reactions and drug-disease interactions. Evidence suggests that this 
approach is worthwhile: a recent Cochrane review reported the efficacy of topical NSAIDs were 
comparable to systemic NSAIDs; that the numbers needed to treat (NNT), as defined by a 50% 
reduction in pain scores, for topical diclofenac and topical ketoprofen were 9.8 and 6.9 [44]. The 
same review also reported that, although the reporting of systemic effects of topical NSAIDs was 
generally of poor quality, there was no difference in observed effects between topical NSAIDs and 
placebo. This approach is also reflected in the UK National Institute for Health and Care Excellence 
(NICE) guidance when advocating the use of NSAIDs in older people: in osteoarthritis, paracetamol 
and topical NSAIDs are considered first line treatments; if oral NSAIDs are indicated, they should be 
co-prescribed with a proton pump inhibitor (PPI) to reduce the possibility of developing GI irritation 
[45]. Using topical NSAIDs appears to be acceptable to older people who believe topical NSAIDs are 
less toxic than systematic NSAIDS, and that they have a localised, rather than a generalised, effect; 
this is an important consideration in decision-making from both a patient, and a prescriber 
perspective [46].  
 
The example of a chronic condition in an older person influencing a treatment choice or changing a 
specific formulation can also be extended to excipients contained within a medication. Indeed, 
medications can often contain high amounts of sodium or potassium, which can be problematic in 
some chronic diseases. For example, Gaviscon Advance® Liquid, which contains sodium alginate and 
potassium bicarbonate as active ingredients (specifically each 10 mL dose contains 4.6 mmol sodium, 
and 2.0 mmol of potassium), is often used to treat dyspepsia [47]. Due to the high sodium and 
potassium content contained in Gaviscon Advance®, this preparation should be avoided in people 
with renal impairment, hypertension or heart failure – all of which are common chronic conditions in 
older people. Similarly, due to the problems associated with a reduced capacity to swallow in older 
people as discussed in the previous section, some prescribers advocate the use of effervescent 
formulations (e.g. soluble paracetamol tablets) as means of delivering drugs to older people. 
Unfortunately, this approach can also be problematic due to effervescent formulations containing 
high amounts of sodium chloride. For example, effervescent paracetamol formulations can contain 
16.9 mmol of sodium per 500 mg paracetamol tablet [48], and on the basis of the WHO 
recommended daily intake of sodium being less than 85 mmol per day for adults [49], a patient using 
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4 grams of paracetamol daily would be taking more than the recommended daily allowance of 
sodium – without even considering dietary intake. In comparison to other foods that are considered 
high in salt, 8 effervescent paracetamol 500 mg tablets contain nearly twice the amount of salt than 
100 g of bacon [50]. In view of the elevated sodium levels in these products, there have been 
published case reports linking soluble paracetamol to hypertension [51], and hypernatraemia [52]; a 
further nested case controlled study using the Clinical Practice Research Datalink (CPRD) showed 
that exposure to sodium-containing effervescent formulations was positively – and significantly – 
associated with increased odds of adverse cardiovascular events [53].  
 
As well as increasing the potential for drug-disease interactions, some long-term conditions also 
influence the physical ability of an older person to use a medication. Examples of this include: 
difficulty in swallowing oral medication (e.g. people with Parkinson’s disease progressively lose 
control of the muscles in the mouth and throat); inability to correctly use an inhaler or eye drops 
(e.g. people with arthritis may not have the grip strength or dexterity required to activate the 
inhaler); and, difficulty in removing medication from packaging (e.g. people with visual impairment 
may struggle to see small tablets).  Given the challenges of multimorbidity in the ageing population, 
an older person presenting with, for example, hypertension, depression, Parkinson’s disease, and 
osteoarthritis represents a significant challenge from a drug delivery point of view. There have been 
simple steps taken by the pharmaceutical industry to help overcome these challenges; these 
approaches include formulating oral medications as effervescent or dispersible tablets to aid 
swallowing; making tablets larger in size, and using colour to help with the identification and 
removal from packaging, and developing different inhaler types or devices that can be activated with 
less strength or grip. Although these attempts have been helpful, there is still much research to be 
done in this area to ensure patients with multimorbidity can effectively – and safely – use their 
medications from a physical point of review. This has been highlighted in a study by Shirmanesh and 
Jones who compared the physical ability of people with and without rheumatoid arthritis to use four 
commonly used inhaler devices [54].  The authors showed that for a pMDI, only 50.0% of 
rheumatoid arthritis patient could complete all of the necessary steps required in order to use the 
inhaler device successfully, compared to 91.0% of patients without rheumatoid arthritis; the worse 
performing inhaler was the HandiHaler®, where only 15.0% of people with rheumatoid arthritis 
could complete all of the necessary steps, when compared to 94.0% of patients.  
 
In summary, when prescribing a medication to an older person, it is important to view the patient 
holistically and consider any long-term conditions of the patient in any prescribing decisions, as this 
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may influence the choice of medication, the dose of medication, the treatment duration, or the 
formulation of the medication. As well  the drug therapy, the prescriber should also consider the 
excipients contained within a medication, and if the patient can physically use the medication as 
these aspects, too, could impact on the patients overall health. 
 
4. . Safe and effective packaging of medication: key challenges and considerations among older 
people 
In addition to drug choice and formulation considerations, the packaging of a medication is also an 
important factor when supplying medications to older people – this is particularly evident for older 
people with visual or cognitive impairment. When prescribing medication to a patient with physical 
of cognitive impairment, it is important for the clinician to assess the patient’s capacity to use self-
manage their own medication; a number of tools have been developed to achieve this [55]. Indeed, 
there are many cases where harm has occurred to patients as a result of the medication being mixed 
up with another medication. With more and more medications being developed, there are now 
many examples of medications that look-a-like (Figure 3) and sound-a-like (Table 3); this refers to 
when names of medications have orthographic similarities and/or have similar phonetic names. It is 
estimated that, in the US, confusion between look-a-like or sound-a-like names contribute to 
approximately 25% of all medication errors [56], which, sadly, cause a number of deaths [57]. While 
there is an abundance of literature exploring the role of packaging in prescribing and dispensing 
errors [58], there is also the possibility that patients – particularly older adults with multimorbidity 
and polypharmacy – can mix up their medications, which can potentially cause harm. Although the 
packaging of the medication may not be at the front of a prescribers mind during an episode of 
prescribing, look-a-like or sound-a-like names should specifically be considered by the pharmacist at 
the point of medication supply to ensure that chances of patient harm by mixing up medication is 
reduced. 
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Figure 3: Examples of medication packaging that ‘look-a-like’: atenolol 50 mg tabs (beta-blocker) 
versus sertraline 50 mg tabs (selective serotonin reuptake inhibitor) [left]; promethazine 25 mg/5 mL 
liquid (antihistamine) versus folic acid 2.5 mg/5 mL liquid (folate) [right]. 
 
Some possible strategies to mitigate against this is to design packaging that allows medication to 
stand out, such as using contrasting colours and increasing the text size on the packaging. Tallman 
lettering – where part of a drugs name is written in capital letters to distinguish it from other similar 
sounding drugs – has also been used as an approach to prevent medication errors in older people; as 
an example, amlodipine and atorvastatin, two commonly prescribed sound-a-like medications in 
older people, would be written as amLODIPine and ATORVAstatin. The use of Tallman lettering on 
drug packaging has been endorsed by various organisations, including the US Food and Drug 
Administration and, as such, is commonly used in clinical practice [59]; however, despite this 
widespread use, there is conflicting evidence in the literature if Tallman lettering actually prevents 
or reduces name confusion errors [60].  
Table 3: Common medications that ‘sound-a-like’. 
Medication Sounds like Possible consequences of mix-
up 
Aminophylline (xanthine 
bronchodilator) 
Amitriptyline (tricyclic 
antidepressant) 
Deterioration of asthma 
symptoms; drowsiness; 
increased risk of fall 
Amiloride (potassium 
sparing diuretic) 
Amiodarone (antiarrhythmic) Development of cardiac 
arrhythmias 
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Amlodipine (calcium 
channel blocker) 
Atorvastatin (statin) Increase in blood pressure 
Bisoprolol (beta-blocker) Bisacodyl (stimulant laxative) Increase in heart rate/elevation 
of blood pressure; diarrhoea 
Carbamazepine 
(antiepileptic) 
Carbimazole (antithyroid) Reduced seizure control; 
reduced thyroid function 
Citalopram (SSRI) Celecoxib (NSAID) Decline in mood; increase in GI 
adverse effects  
Digoxin (cardiac glycoside) Doxepin (SSRI) Drowsiness; increased risk of fall  
Lofepramine (tricyclic 
antidepressant) 
Loperamide (antidiarrhoeal) Decline in mood; constipation 
Prednisolone (a 
corticosteroid) 
Propranolol (beta-blocker) Decline in respiratory symptoms 
Tramadol (opioid analgesic) Trazadone (antipsychotic) Lack of pain control; 
drowsiness; increase risk of fall 
 
Another example of where the pharmaceutical industry has worked with medication regulators to 
modify drug packaging to improve the safe and effective use of medication is in Alzheimer’s disease. 
Since 2016, in the UK, all blister packs of medication for Alzheimer’s disease are marked with the 
days of the week in order to reduce confusion when patients take their medication [61]. While this is 
encouraging, given that many people with dementia also have other chronic diseases, more could be 
done to improve the packaging of other medicines to make them more suitable for older people 
with dementia.  
Unfortunately there are also examples where, despite intervention from the pharmaceutical 
industry, the packaging and formulation of a medicine remain a problem to patient safety in older 
adults. Indeed, there has also been cases where older patients have mixed up different formulations 
of the same drug or different strengths of the same drug – which had had disastrous consequences 
for patients. One significant example of this is with oral methotrexate, which can be used to treat 
inflammatory bowel disease, rheumatoid arthritis, and psoriasis; in the UK, it is available as a 2.5 mg 
tablet, and as a 10 mg tablet. Despite varying the packaging design, the two tablet formulations 
could look visually similar, and when a mixture of the two strengths of methotrexate was prescribed, 
there were occasions where the medicines were mixed up, which lead to a number of fatalities. To 
mitigate against this risk, many healthcare organisations in the UK now recommend that 
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methotrexate 10 mg tablets are not prescribed for any indication, and that all doses of methotrexate 
are made up from 2.5 mg tablets.  
 
Another example is with the opioid analgesic, oxycodone; it is available as modified released tablets 
to be prescribed every 12 hours, and as an immediate release capsule to be prescribed every 4 to 6 
hours.  Despite the different formulations of oxycodone (tablets and capsules), there have been 
reports where older patients have mixed them up – potentially resulting in overdose of oxycodone 
[62].  In view of this, in a similar approach to the prescribing of methotrexate 10 mg tablets, many 
healthcare organisations do not recommend the prescribing of oxycodone immediate release 
capsules; instead, to minimise the risk of confusion, it is recommended that oxycodone liquid is 
prescribed to treat pain alongside modified release oxycodone. Clearly, the decision for any 
healthcare organisation to not prescribe a specific medication in older adults owing to the risk in 
patient safety is a drastic one. While there has been advancements in recent years concerning the 
packaging of medication for older people, more could be done to help older people use their 
medication more safely and effectively. This is certainly a priority for future research. 
5. Adherence and administration: impact on drug delivery and formulation in older people 
Adherence to medicines is a modifiable factor within the process of optimising therapy and, 
therefore, improving it has the potential to improve patient outcomes. Patients who adhere to 
treatment are, on average, three times more likely to experience good health outcomes, compared 
to patients who are not adherent to treatment [63]. This can be challenging in older people as they 
often use complex medication regimens that result in a high pill burden and polypharmacy.  At 
present, however, it is estimated that around 50% of patients do not take their medicines as 
prescribed by either completely missing doses [64] or taking a different dose than was prescribed. 
This non-adherence is more commonly associated with patient’s taking less medicine, rather than 
taking more medicine, which has the potential to result in overdosing [65]. Occasional non-
adherence is also an issue in older people, with over 85% of patients being non-adherent for some of 
the time and then reverting to following prescribed directions [66]. Overall, the challenges of non-
adherence in older people has significant effects in terms of lost health gain and further morbidity 
and mortality; for example, a study by Banik and Ray suggested that more than 125,000 people in 
the US died as a consequence of poor adherence to prescribed medication [67]. [68]. Age is an 
important factor when considering adherence in older people, but studies have shown the 
relationship between age and adherence is complex.  Rolnick et al who undertook a retrospective 
analysis of patients with eight different conditions measured medication possession ratios (MPR) 
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and defined any patient with an MPR of >80% as being adherent. Results of the study showed that 
older patients were not always less adherent and, in certain disease states, such as hypertension, 
hyperlipidaemia, asthma/COPD, diabetes and osteoporosis, they demonstrated marginally better 
adherence than younger patients [69]. In view of these findings, it would seem that age alone is not 
a good predictor of potential non-adherence to treatment [70]; however, there are undoubtedly 
challenges for older patients with multimorbidity, some of these are discussed in further detail 
below. A range of patient-related factors (e.g. polypharmacy, swallowing difficulties, and medication 
regimen complexity) and the medicine product design (e.g. different formulations) can lead to poor 
adherence in older adults. 
 
5.1 Polypharmacy and regimen complexity 
 
An important consideration in older adults is that polypharmacy – which is commonly observed in 
older people – may increase the risk of developing drug interactions and adverse effects, which, in 
turn, may influence a patient’s decision to adhere to treatment [71]. Another important issue for 
many older people with complex medicine regimens is the availability of the caregiver to provide 
reminders to take medicines. Indeed, in a survey study by Smith et al who investigated the 
experiences of caregivers who manage medications for older people, one of the key themes 
identified was the challenges of assisting people to take their medicines and the frequency with 
which patients need to be reminded to physically take their treatments [72].  
 
As a strategy to rationalise the complexity of medication regimens, the use of fixed dose 
combinations or ‘polypills’ have been shown to be beneficial. Selak et al examined the effect of a 
fixed dose combination of a statin, antiplatelet and two or more antihypertensive agents amongst 
513 patients (average age 62 years of age) in New Zealand with high cardiovascular risk. The study 
demonstrated that the patients taking the fixed dose combination had better adherence compared 
to those using standard care; interestingly, however, despite the improved adherence, there was no 
statistical difference of cardiovascular risk factors between groups [73]. Systematic review of clinical 
outcomes associated with medication regimen complexity in older people has found mixed evidence 
[74]. At present, there is moderate-quality evidence that medication regimen complexity is 
associated with non-adherence.[75]. Other approaches that can be used by health professionals to 
simplify regimen complexity may include use of long-acting formulations, consolidation of dose 
times and avoid the need for tablet splitting. Validated tools such as the Medication Regimen 
Simplification Guide for Residential Aged CarE (MRS GRACE), can assist clinicians to identify 
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opportunities to simplify medication regimens among older adults residing in aged care facilities 
[76]. 
 
5.2 Formulation considerations 
 
As discussed already, the ability of an older person to swallow a dosage form or to have sufficient 
manual dexterity and vision to use other delivery mechanisms, such as inhalers or eye drops, has the 
potential to influence adherence, and thus the overall delivery of a medicine. The acceptability of a 
medicinal product has previously been defined in the literature as ‘the overall ability of the patient 
and caregiver to use the medicinal product as intended or authorised’ [77]. The reality of achieving 
this within the care of older people is influenced by a number of challenges. In the context of taking 
medicines, people who have swallowing difficulties are more likely to be exposed to medication 
errors (e.g. through unauthorised tablet crushing)[78]. [79]. ,‘[80].  
 
Moreover, the use of soluble, oral dispersible or chewable tablets is also an option for patients who 
have dysphagia. While this approach may improve medicine adherence in older people, there are 
still challenges: these formulations are not commercially available for all medicines, and for the 
preparations that are available, they often have a high sodium load, which, as we have discussed 
previously, can be problematic for older people with hypertension and cardiovascular morbidity [81] 
[53]. There is also some evidence to suggest that the carbon dioxide produced as a consequence of 
the effervescence has the potential to improve swallowing via stimulation of the oral cavity [82]. 
There is clearly a balance to be considered when prescribing a soluble preparation for an older 
person: chewable tablets are of limited use in older people, partially due to the decline in chewing 
ability, which is associated with loss of muscle mass and declining oral health. The products available 
on the market are highly variable and whilst they are all marketed as ‘chewable’, they all vary in 
terms of how easy it is for an older person to manage [83]. Oral dispersible tablets tend to be well 
tolerated by patients: they have been described to taste reasonably good and are potentially easier 
to swallow as they require less effort and avoid the need for large volumes of sodium-rich water to 
be consumed alongside them. [84] They have potential to help in the delivery of medicines to older 
people, but, unfortunately, such formulations are, at present limited. Depending on co-morbid 
conditions and the commercial availability of the product in question different routes may be more 
or less suitable depending on individual circumstances.  
 
Inhalers 
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Drugs delivered to the lungs via inhaled formulations can be challenging to use and may lead to poor 
medication adherence. Inhalers of all types require co-ordination in order for a drug to be delivered 
effectively. Older people commonly demonstrate poor inhaler technique [85] – usually as a 
consequence of muscle weakness in the hands, lack of co-ordination, or cognitive decline [86]. 
Evidence for poor inhaler technique exists for older people using all types of device, including when 
inhalers are combined with spacer devices [87]. Importantly, poor inhaler technique is clearly linked 
with worsening symptoms, the use of rescue therapy, such as oral corticosteroids, and hospital 
admission [87]. Although the literature has shown that older people can have poor inhaler technique 
with all devices, the choice of device is still an important consideration in his patient group.  For 
example, studies have shown that adherence to treatment with inhaled corticosteroids is better for 
patients using dry powder inhalers (DPIs), when compared to using pressurised metered dose 
inhalers (pMDIs) [88]. This finding may be tempered to a degree by the issue of inspiratory effort 
and being able to generate sufficient flow to ensure that dry powder devices work properly. This is a 
concern for older patients who may have reduced peak inspiratory flow rate as a result of ageing per 
se, or as a consequence of comorbid disease, such as COPD [89] . Reduced inspiratory effort has the 
potential to limit the fraction of dose in the correct particle size range to be inhaled and deposited in 
the lungs. Instead, there are a greater number of larger particles produced, which are not inhaled, 
but deposited in the mouth and oropharynx, thus creating the potential for adverse effects, such as 
oral candidiasis, which, in turn, may influence the desire to adhere. The presumption, therefore, that 
DPIs are easier to handle, and more appropriate for older people is not always necessarily the case 
and, in fact, handling errors with DPIs are not lower than those associated with pMDIs [87]. The 
issue of supporting older patients to use inhalers more effectively is discussed further below.   
   
5.3 Interventions to improve medication adherence and administration 
 
Whilst the delivery of medicines to older patients does have complexities, some of which are difficult 
to overcome, one of the main areas that can be improved within the medication-taking process is to 
implement support mechanisms to help people to be more adherent. This is notwithstanding the 
fact that changes in adherence without medication review can lead to problems: patients who have 
been non-adherent and suddenly begin to take their medications as prescribed may experience 
adverse effects as a consequence of effectively starting treatment at a higher dose or with more 
medicines than is necessary. Adherence to suboptimal treatment or harmful therapy is linked to an 
increased risk of mortality [90]. A medicine review prior to implementation of an adherence 
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intervention will help rationalise treatment regimens, remove any inappropriate medicines and 
ensure the most appropriate dosage form is used.   
 
Overall, there is uncertainty as to the effectiveness of interventions designed to improve medicines 
use and improve adherence in older people. Equally, there is a relative lack of studies that 
specifically examine the effects of polypharmacy and multimorbidity on adherence; this is a clear 
future research priority given these are the issues faced by an older patient population [91]. At 
present, the literature is dominated by intervention studies that focus on single disease states in 
specific patient groups, which employ relatively simple interventions, such as reminders to take 
medicines [92]. To further compound matters, medicines adherence is often arbitrarily split into 
‘intentional’ and ‘unintentional’ non-adherence within the literature. As a consequence, many of the 
interventions discussed in the literature are designed to target unintentional adherence and remind 
patients to take their medication. Another approach that has been employed is the use of reminder 
packaging as a way of managing patients with polypharmacy in an attempt to reduce unintentional 
non-adherence. The evidence to support this intervention is inconclusive; marginal improvements 
have been observed in adherence, although there is limited information on how this approach 
improves health outcomes [93]. More complex interventions around adherence do show some 
positive results and are of benefit in long-term care. These interventions are combinations of 
organisational support, such as improving the convenience of care, electronic reminders, such as 
sending text messages, smart packaging or telehealth interventions and input from multidisciplinary 
teams, often involving pharmacist-led initiatives. Despite the improvements in adherence seen with 
such interventions, there is limited evidence to suggest that a significant clinical benefit can be 
observed: where outcomes have been measured, they tend to be specific clinical measures, such as 
blood pressure or INR, rather than end-point outcomes, such as mortality [64].  Use of dose 
administration aids, which organise doses of tablets and capsules according to when they should be 
taken, can improve medication management and non-intentional adherence [94]. Dose 
administration aids may be particularly useful for patients who struggle to manage complex 
medicine regimen that consists of regularly scheduled medications, or solid oral dose forms that are 
suitable for packing. 
 
 
As discussed above, the challenges for older people using inhaled therapies can result in worsening 
health and increased mortality. Evidence suggests that many people do not receive good education 
around how to use their inhalers [87] and even when this does happen, the retention of information 
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is poor, which results in suboptimal inhaler use within a short period of time [95]. In view of this, 
Bouwmeetser et al. implemented a pharmacist-led programme to improve inhaler use amongst a 
community-dwelling group of older patients. The intervention consisted of a baseline test followed 
by education on how to use inhaler devices then another test to examine improvement in 
knowledge. Outcomes from this study showed that participants had improved knowledge of inhaler 
technique, which was sustained over a 6-week period. The participants were also provided with an 
automatic refill of their prescription for inhalers and thus had sufficient supplies [86]. Similar findings 
have been observed in other studies; for example, Lindenmeyer et al examined interventions 
focused on improving adherence to medications in individuals with type 2 diabetes. The results 
showed an improvement in HbA1c, following a pharmacist-led integrated management and 
education programme. The authors concluded that although improvement in HBA1c were observed 
this could not be directly linked to an improvement in adherence [96].  
 
The use of medicines review and deprescribing – defined as ‘the process of withdrawal of an 
inappropriate medication, supervised by a health care professional with the goal of managing 
polypharmacy and improving outcomes’ [97]- for older people is a logical step to address some of 
the issues raised above. It has been suggested that deprescribing processes have the potential to 
improve adherence to treatment by educating people about their medicines and making them 
partners in the decision to take a medicine, irrespective of any net reduction in pill burden. Other 
proposed benefits of deprescribing on adherence are reduction in financial costs for those 
individuals who have to pay for their medicines and potential resolution of adverse drug reactions as 
a consequence of complex polypharmacy. At present, however, there is very little evidence of note 
to support these claims: most of the literature defines cost savings and reductions in overall 
medicine use, but is not specifically powered to examine changes in important clinical outcomes, 
such as hospital admission, morbidity or mortality [98]. Given the evidence that polypharmacy does 
influence adherence, it would seem to be a plausible hypothesis and one worthy of further 
investigation in randomised control trials.  
 
Conclusion 
Delivering the right treatment at the right dose to older people is a challenging task. Older people 
have complex health care needs, which are rarely addressed in drug delivery research to inform the 
development of medicines suitable for use in this population and to ensure therapeutic outcomes. 
Drug development cycle needs to be tailored to ensure that new drugs can be safely, effectively, and 
efficiently delivered to older people. The pharmaceutical manufacturing industry should support 
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these efforts by using advanced manufacturing technology to provide affordable, convenient and 
easy-to-use drug forms. Importantly, it is essential to include older people and caregivers in drug 
design development process to assess usability, packaging and acceptability of medications, and 
regulatory institutions should request information about drug delivery and acceptability of 
formulations for older people. 
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